In this section
This document guides how to prescribe, order, administer and manage patients receiving intravenous immunoglobulin (IVIg) at the RCH.
Record the consent for the administration of IVIg on the Patient Consent to Blood Products MR634/A.
Inform the patient of:
Consent is valid for the duration of the admission. However, consent for patients receiving regular IVIg is valid for 12 months. This should be indicated on the MR634/A.
Print and provide the patient/family information explaining IVIg:
Consumer information produced by manufactures:
Administration rates vary between
products and presentations.
IVIg products and presentations are
Flebogamma® 5% 2
Note: do not administer to children
under 2 years or with fructose intolerance
Flebogamma® 10% 2
Note: do not administer to children under 2 years or with
in 25 ml
in 100 ml
in 200 ml
5g in 50 ml
10g in 100 ml
20g in 200 ml
40g in 400 ml
0.5g in 10 mls
2.5g in 50 ml
5g in 100 ml
10g in 200 ml
20g in 400 ml
increase every 30 minutes only if tolerated
Maximum of 240 ml/hr
Adverse events or
Report any adverse events or near miss via VHIMS. These will be reported to the Transfusion Committee who will report to CSL and the TGA as needed.
Overdose of IVIg may lead to fluid overload and hyperviscosity, particularly in patients with renal impairment.